The above results revealed that TFAP2A targets ESR2 and activates the MAPK signalling pathway, suggesting that inhibiting ESR2 may sensitise NSCLC cells to targeted therapy. This evidence concerns the gene TFAP2A and non-small cell lung carcinoma.